company background image
PRQR logo

ProQR Therapeutics NasdaqCM:PRQR Stock Report

Last Price

US$1.79

Market Cap

US$147.0m

7D

-3.5%

1Y

0.8%

Updated

19 Jul, 2024

Data

Company Financials +

ProQR Therapeutics N.V.

NasdaqCM:PRQR Stock Report

Market Cap: US$147.0m

ProQR Therapeutics N.V. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for ProQR Therapeutics
Historical stock prices
Current Share PriceUS$1.79
52 Week HighUS$3.29
52 Week LowUS$1.11
Beta0.42
11 Month Change7.21%
3 Month Change-10.30%
1 Year Change0.85%
33 Year Change-67.49%
5 Year Change-78.93%
Change since IPO-87.88%

Recent News & Updates

ProQR Therapeutics N.V. (NASDAQ:PRQR) Investors Are Less Pessimistic Than Expected

Jul 15
ProQR Therapeutics N.V. (NASDAQ:PRQR) Investors Are Less Pessimistic Than Expected

Broker Revenue Forecasts For ProQR Therapeutics N.V. (NASDAQ:PRQR) Are Surging Higher

May 29
Broker Revenue Forecasts For ProQR Therapeutics N.V. (NASDAQ:PRQR) Are Surging Higher

Recent updates

ProQR Therapeutics N.V. (NASDAQ:PRQR) Investors Are Less Pessimistic Than Expected

Jul 15
ProQR Therapeutics N.V. (NASDAQ:PRQR) Investors Are Less Pessimistic Than Expected

Broker Revenue Forecasts For ProQR Therapeutics N.V. (NASDAQ:PRQR) Are Surging Higher

May 29
Broker Revenue Forecasts For ProQR Therapeutics N.V. (NASDAQ:PRQR) Are Surging Higher

Is ProQR Therapeutics (NASDAQ:PRQR) Using Too Much Debt?

Apr 03
Is ProQR Therapeutics (NASDAQ:PRQR) Using Too Much Debt?

Health Check: How Prudently Does ProQR Therapeutics (NASDAQ:PRQR) Use Debt?

Nov 28
Health Check: How Prudently Does ProQR Therapeutics (NASDAQ:PRQR) Use Debt?

Is ProQR Therapeutics (NASDAQ:PRQR) Using Too Much Debt?

Jul 30
Is ProQR Therapeutics (NASDAQ:PRQR) Using Too Much Debt?

Despite Lacking Profits ProQR Therapeutics (NASDAQ:PRQR) Seems To Be On Top Of Its Debt

Mar 17
Despite Lacking Profits ProQR Therapeutics (NASDAQ:PRQR) Seems To Be On Top Of Its Debt

ProQR says EU regulator seeks additional trial for lead candidate

Aug 11

Here's Why ProQR Therapeutics (NASDAQ:PRQR) Can Manage Its Debt Despite Losing Money

Nov 10
Here's Why ProQR Therapeutics (NASDAQ:PRQR) Can Manage Its Debt Despite Losing Money

Investment Case On ProQR Therapeutics Gets More Enticing

Oct 01

ProQR Therapeutics (NASDAQ:PRQR) Has Debt But No Earnings; Should You Worry?

Aug 04
ProQR Therapeutics (NASDAQ:PRQR) Has Debt But No Earnings; Should You Worry?

ProQR Therapeutics: Looks Interesting Ahead Of Next Year's Pivotal Data

Jun 20

It's Unlikely That ProQR Therapeutics N.V.'s (NASDAQ:PRQR) CEO Will See A Huge Pay Rise This Year

May 13
It's Unlikely That ProQR Therapeutics N.V.'s (NASDAQ:PRQR) CEO Will See A Huge Pay Rise This Year

ProQR Therapeutics offers a de-risked opportunity: Stifel

May 03

If You Had Bought ProQR Therapeutics' (NASDAQ:PRQR) Shares A Year Ago You Would Be Down 42%

Mar 08
If You Had Bought ProQR Therapeutics' (NASDAQ:PRQR) Shares A Year Ago You Would Be Down 42%

Could The ProQR Therapeutics N.V. (NASDAQ:PRQR) Ownership Structure Tell Us Something Useful?

Feb 01
Could The ProQR Therapeutics N.V. (NASDAQ:PRQR) Ownership Structure Tell Us Something Useful?

ProQR concludes enrollment in mid-stage cell therapy trial in a rare eye disorder

Jan 07

ProQR Therapeutics (NASDAQ:PRQR) Has Debt But No Earnings; Should You Worry?

Dec 28
ProQR Therapeutics (NASDAQ:PRQR) Has Debt But No Earnings; Should You Worry?

A Look At ProQR Therapeutics' (NASDAQ:PRQR) Share Price Returns

Dec 01
A Look At ProQR Therapeutics' (NASDAQ:PRQR) Share Price Returns

ProQR reports Q3 results

Nov 16

Shareholder Returns

PRQRUS BiotechsUS Market
7D-3.5%-0.1%-1.9%
1Y0.8%11.1%19.4%

Return vs Industry: PRQR underperformed the US Biotechs industry which returned 12% over the past year.

Return vs Market: PRQR underperformed the US Market which returned 20.2% over the past year.

Price Volatility

Is PRQR's price volatile compared to industry and market?
PRQR volatility
PRQR Average Weekly Movement5.5%
Biotechs Industry Average Movement10.7%
Market Average Movement5.9%
10% most volatile stocks in US Market14.9%
10% least volatile stocks in US Market2.9%

Stable Share Price: PRQR's share price has been volatile over the past 3 months.

Volatility Over Time: PRQR's weekly volatility (6%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2012157Daniel de Boerwww.proqr.com

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company’s products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1). It also develops various other early-stage research programs, including AX-1005 for undisclosed targets in CVDs; AX-2402, which focuses on Rett syndrome; AX-2911 for nonalcoholic steatohepatitis (NASH); AX-0601 for obesity and Type 2 diabetes; and AX-9115 for rare metabolic condition, as well as various other targets.

ProQR Therapeutics N.V. Fundamentals Summary

How do ProQR Therapeutics's earnings and revenue compare to its market cap?
PRQR fundamental statistics
Market capUS$146.99m
Earnings (TTM)-US$29.20m
Revenue (TTM)US$11.48m

12.7x

P/S Ratio

-5.0x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
PRQR income statement (TTM)
Revenue€10.56m
Cost of Revenue€0
Gross Profit€10.56m
Other Expenses€37.40m
Earnings-€26.84m

Last Reported Earnings

Mar 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-0.33
Gross Margin100.00%
Net Profit Margin-254.28%
Debt/Equity Ratio12.5%

How did PRQR perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.